Aeglea Biotherapeutics, Inc.
|Number of Estimates|
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Market Cap: 230 Million
Primary Exchange: NASDAQ
Shares Outstanding: 29 Million
Float: 24 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 1480 trading days
From: 2016-04-08 To: 2020-01-17
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|